Report a data issue, formatting problem, or request follow-up. Our team responds within one business day.
Be the first to review this report.
L (+) Ergothioneine is a naturally occurring sulfur containing derivative of L histidine with the molecular formula C9H15N3O2S and a molecular mass of 229.30 g/mol. Its molecular structure contains a trimethylated histidine backbone and a sulfur substituted imidazole ring, forming an amino acid betaine with a permanent zwitterionic character. The molecule exists in equilibrium between thiol and thione tautomers. At physiological pH the thione form predominates, which substantially limits spontaneous oxidation and gives ergothioneine greater chemical stability than many conventional low molecular weight thiols. This thione chemistry also permits redox reactions and transition metal coordination while retaining high aqueous solubility. High purity commercial material is typically supplied as a white crystalline powder. The synthetic material assessed by the European Food Safety Authority specifies chemical purity of at least 99.5 percent by HPLC and positive optical rotation consistent with the naturally occurring L configuration. Natural ergothioneine biosynthesis occurs in selected fungi and bacteria through histidine derived sulfur incorporation pathways. Mushrooms contain particularly high concentrations, while lower concentrations occur in beans, cereals, animal tissues and other foods through biological uptake and food chain transfer. Humans do not possess a known endogenous biosynthetic pathway for ergothioneine and obtain it from dietary sources. Absorption and tissue retention are strongly associated with the SLC22A4 transporter, commonly termed OCTN1 or the ergothioneine transporter, which mediates intestinal uptake, cellular accumulation and renal reabsorption. Ergothioneine can consequently accumulate in erythrocytes and several tissues despite relatively low dietary concentrations. Its thione dominated chemistry gives the molecule resistance to autoxidation and enables reactions with reactive oxygen and nitrogen species and coordination with selected metal ions. These physicochemical properties underpin its use as a functional ingredient, while its precise physiological roles in humans remain an active area of biochemical research. Industrial L (+) Ergothioneine is manufactured principally by microbial fermentation, enzyme catalyzed synthesis and chemical synthesis. Commercial fermentation routes use engineered microorganisms carrying ergothioneine biosynthetic enzymes, with current FDA GRAS records documenting production using engineered Escherichia coli strains. Chemical production has also been established commercially and was the manufacturing basis of the synthetic material evaluated by EFSA. Enzyme catalyzed routes convert histidine derived precursors through selective sulfur incorporation reactions and are currently used by commercial ingredient manufacturers. These technologies produce chemically equivalent L ergothioneine when stereochemical configuration, molecular identity, purity and impurity specifications are controlled. Commercial material is used in dietary supplements, foods and beverages, cosmetics and personal care formulations, with food use subject to jurisdiction specific regulatory requirements. The European Union currently lists L ergothioneine as an authorised novel food for specified food categories and food supplements.
According to APO Research, Inc, the global L (+) Ergothioneine market was valued at USD 68.53 million in 2025 and is expected to reach USD 84.17 million in 2026 and USD 191.86 million by 2032, representing a CAGR of 14.72% from 2026 to 2032. Global sales volume is estimated at 25.86 t in 2025 and 33.40 t in 2026, reaching 107.79 t in 2032, equivalent to a volume CAGR of 21.56%. The weighted ex factory net price is estimated at USD 2,650.00 per kg in 2025, USD 2,520.00 per kg in 2026 and USD 1,780.00 per kg in 2032, corresponding to an average annual price decline of 5.63% during 2026 to 2032. Effective manufacturing capacity is estimated at 72.50 t in 2025, 92.01 t in 2026 and 189.97 t in 2032, while utilization increases from 35.67% to 36.30% and 56.74%, respectively. The value expansion therefore comes primarily from higher physical consumption, rising utilization and broader downstream formulation volumes as fermentation productivity and purification economics reduce unit cost.
China is expected to contribute the largest manufacturing increment through GeneIII Biotechnology, Chuanning Biotechnology, Shanghai EGT Synbio, Readline Biotech, SIYOMICRO, Bloomage Biotech, Abiochem and other commercial producers. GeneIII reports monthly L (+) Ergothioneine capacity of 3.00 to 5.00 t, equivalent to 36.00 to 60.00 t on an annualized basis, with product purity reaching 99.99%. This disclosed capacity alone exceeds the audited 2026 global sales volume of 33.40 t and provides a direct physical explanation for the relatively low industry utilization rate. SIYOMICRO has reported stable production scale up in a 100.00 t fermenter, while Readline has commissioned two hundred tonne class shared active ingredient production lines in Zhuhai with commercial scale production of ergothioneine. Chuanning exceeded its 11.00 g/L fermentation titer objective and annual production target in 2025. Bloomage commercially produces MitoEGT through one step biosynthesis, and Shanghai EGT Synbio has established commercial biological production of Dr.Ergo. The current FDA GRAS inventory contains four ergothioneine notices. Blue California, Shanghai EGT Synbio and GeneIII have received FDA no questions letters. Abiochem remains under review.
Fermentation is expected to account for the largest incremental production volume through 2032 as strain productivity, fermentation titer, reactor scale, downstream recovery and crystallization yield improve. Enzymatic synthesis and chemical synthesis remain relevant for selected manufacturing configurations and purity specifications. Dietary supplements are expected to remain the largest application by value, followed by food and beverages and cosmetics and personal care, with pet nutrition representing a smaller commercial application. Regulatory inclusion levels provide a useful physical demand anchor. The European Union permits up to 30.00 mg per day in food supplements for the general population, 25.00 mg per kg in alcohol free beverages and milk based drinks, 40.00 mg per kg in fresh milk products, 200.00 mg per kg in cereal bars and 250.00 mg per kg in chocolate confectionery. At 30.00 mg per day, 1.00 t of L (+) Ergothioneine corresponds to approximately 33.33 million supplement consumption days. At 25.00 mg per kg, 1.00 t can theoretically supply 40,000.00 t of beverage at the permitted maximum inclusion level. These low unit dosages allow large downstream finished product volumes to absorb relatively modest ingredient tonnage, while continued price reductions materially enlarge the addressable formulation base. Commercial demand is recurrent because L (+) Ergothioneine is consumed within finished formulations and replenished with continuing supplement, food, beverage, cosmetic and pet nutrition production.
This report quantifies the global L-(+)-Ergothioneine market in terms of revenue (US$ million) and, where applicable, sales volume (kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of L-(+)-Ergothioneine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of L-(+)-Ergothioneine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of L-(+)-Ergothioneine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
You may also be interested in
